| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | OSU-03012 | GDSC1000 | pan-cancer | AAC | 0.0015 | 1 |
| mRNA | BRD-K34485477 | CTRPv2 | pan-cancer | AAC | -0.0031 | 1 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | 0.0012 | 1 |
| mRNA | CIL41 | CTRPv2 | pan-cancer | AAC | 0.0019 | 1 |
| mRNA | GSK2126458 | GDSC1000 | pan-cancer | AAC | 0.0012 | 1 |
| mRNA | KHS101 | CTRPv2 | pan-cancer | AAC | 0.0012 | 1 |
| mRNA | BRD-K03536150 | CTRPv2 | pan-cancer | AAC | -0.0012 | 1 |
| mRNA | JW-480 | CTRPv2 | pan-cancer | AAC | 0.0011 | 1 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.00089 | 1 |
| mRNA | GSK1059615 | CTRPv2 | pan-cancer | AAC | -0.0011 | 1 |